Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitori
Coherus: Transitioning To Its Next Avatar As An R&D Company
08:00am, Thursday, 25'th Mar 2021
Coherus: Transitioning To Its Next Avatar As An R&D Company
Coherus Management to Present at Upcoming Investor Conferences
08:45am, Thursday, 25'th Feb 2021
REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferenc
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2020 Results - Earnings Call Transcript
10:44pm, Wednesday, 24'th Feb 2021
Coherus BioSciences, Inc. (CHRS) CEO Denny Lanfear on Q4 2020 Results - Earnings Call Transcript
Coherus BioSciences (CHRS) Misses Q4 Earnings and Revenue Estimates
06:11pm, Wednesday, 24'th Feb 2021
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -52.00% and -3.90%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock
Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results
04:01pm, Wednesday, 24'th Feb 2021
- Product revenues of $476 million for full year 2020, $110 million for the fourth quarter of 2020 - - Expanding late-stage opportunities with Junshi Biosciences immuno-oncology collaboration with f
Earnings Preview: Coherus BioSciences (CHRS) Q4 Earnings Expected to Decline
01:41pm, Thursday, 18'th Feb 2021
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CHRS or ILMN: Which Is the Better Value Stock Right Now?
12:53pm, Thursday, 18'th Feb 2021
CHRS vs. ILMN: Which Stock Is the Better Value Option?
Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review
07:30am, Wednesday, 17'th Feb 2021
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: “CHRS”, “the Company”, “Coherus”) announced that the United States Food and Drug Administration (
Coherus Deal Signals Pivot to New and Crowded Market
05:00pm, Monday, 08'th Feb 2021
Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosciences C
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
03:38pm, Sunday, 07'th Feb 2021
Week In Review: Junshi Signs $1.1 Billion Deal For U.S.-Canada Rights To PD-1
Coherus BioSciences Announces New Employment Inducement Grants
04:01pm, Friday, 22'nd Jan 2021
REDWOOD CITY, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective January 21, 2021, the compensation
Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors
04:01pm, Thursday, 07'th Jan 2021
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointments of Alan C. Mendelson and Mark D. Stolper to its Board
Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 05'th Jan 2021
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the virtual 39th Annual J.P. Mor
Coherus BioSciences Announces New Employment Inducement Grants
04:02pm, Monday, 21'st Dec 2020
REDWOOD CITY, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 17, 2020, the compensation
